Reuters logo
BRIEF-Blueprint Medicines enrolls first patient in BLU-667 Phase 1 clinical trial
March 20, 2017 / 8:09 PM / 6 months ago

BRIEF-Blueprint Medicines enrolls first patient in BLU-667 Phase 1 clinical trial

March 20 (Reuters) - Blueprint Medicines Corp

* Blueprint Medicines announces enrollment of first patient in Phase 1 clinical trial for BLU-667 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below